Benitec Biopharma Inc. (BNTC): Shareholders' Equity
$177.01M
As of 2026-06-30
n/m
3-year compound annual growth
+54.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $177.01M | +81.9% | 2026-09-14, Balance as of period end |
| 2025-06-30 | $97.30M | +105.9% | 2026-09-14, Balance as of period end |
| 2024-06-30 | $47.25M | n/m | 2026-03-20, Balance as of period end |
| 2023-06-30 | $202.0K | -93.0% | 2024-09-26, Balance as of period end |
| 2022-06-30 | $2.88M | -85.6% | 2023-09-21, Balance as of period end |
| 2021-06-30 | $20.01M | +95.4% | 2022-09-02, Balance as of period end |
| 2020-06-30 | $10.24M | -38.3% | 2021-09-20, Balance as of period end |
| 2019-06-30 | $16.59M | n/a | 2020-09-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $177.01M | +81.9% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $151.14M | -0.2% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $107.54M | -26.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $49.87M | +119.3% |
| PepGen Inc. (PEPG) | 2025-12-31 | $147.44M | +24.3% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $159.21M | -14.7% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $183.24M | +83.9% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$122.76M | n/m |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $81.08M | +29.8% |
Compare BNTC, ANRO, LXRX, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗